Design, synthesis, and biological evaluation of KA7, a novel quinolone-based sorafenib analogue with potent anticancer and immunomodulatory activities
Duaa abuarqoub, Ahmed Alshaikh, Marwa Mohammad, Hana'a Khalaf, Nour Albaz, Ali Hmedat · 2025
Read Design, synthesis, and biological evaluation of KA7, a novel quinolone-based sorafenib analogue with potent anticancer and immunomodulatory activities by Duaa abuarqoub, Ahmed Alshaikh, Marwa Mohammad, Hana'a Khalaf, Nour Albaz, Ali Hmedat (2025) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/pmc-12695144.txt.
Description
Duaa Abuarqoub and co-authors made and tested a new cancer compound in 2025 modeled on the drug sorafenib. Sorafenib blocks many kinases but brings toxicity and resistance. Their analogue, KA7, swaps part of its frame for a quinolone scaffold. Lab tests measured killing power on breast, brain, and lung cancer cells, plus effects on immune cells.
KA7 beat sorafenib on brain and lung cells and matched it on one breast line. It pushed cells into death, froze their cycle early, and triggered self-eating. In immune cells it raised calming signals and lowered inflammatory ones. The authors call KA7 a promising lead for further preclinical work.
Catalog record
| CREATOR | Duaa abuarqoub, Ahmed Alshaikh, Marwa Mohammad, Hana'a Khalaf, Nour Albaz, Ali Hmedat |
|---|---|
| YEAR | 2025 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 31 KB |
| VERSION | 1.0 |
| LICENSE | CC BY 4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |